It was a downward slide for the Amicus Therapeutics on Monday when the drug company announced the failure of its drug candidate for Gaucher disease, an enzyme disorder. The shares of Amicus Therapeutics dropped considerably soon after the company came out with the disappointing news about the inefficiency of their drug named Plicera. The shares of Amicus dropped around $2.77, or 32.6 percent to $5.73 in the morning trading.

On Friday, Amicus Therapeutics came out with the news of the failure of their drug candidate Plicera and said that the drug did not appear to work for many patients in the midstage clinical trial as expected and so they had to come out with the sad news. Gaucher disease is an enzyme disorder that can harm the liver and cause neurological complications.

DrStockPick.com Stock Report!

Thursday September 10, 2009

**************************************************************

Concurrent (Nasdaq: CCUR), a worldwide leader in video and media data and advertising solutions, is announcing the international extension of its three-screen strategy to bring open, commercial and intelligent video solutions to television, personal computers and mobile devices. First announced in the U.S. in March 2009, Concurrent’s strategy now leverages the company’s technological expertise to enable its customers to deliver, monetize and drive the future of video around the globe.

Diguang International Development Co., Ltd. (OTC Bulletin Board: DGNG) today announced that Shenzhen Diguang Electronics Co., Ltd. (”Diguang”) was selected as a member of the Standard

Amicus Therapeutics (FOLD) began registration for phase III trial of its investigational drug Amigal for the treatment of Fabry disease and expects to begin the dosing of subjects in the second half of this year. Along with the US FDA, the company has already decided on the primary endpoint of the pivotal trial which will be based on the change in the amount of kidney GL-3, the substrate that accumulates in the cells of Fabry patients.

The trial will consist of a six-month enrollment of approximately 60 subjects who are either new to enzyme replacement therapy (ERT) or have not received ERT for at least six months prior to the start of treatment with Amigal. The Amigal treatment arm dose and regimen will be 150 mg every other day.

Amicus and partner Shire Human Genetic Therapies Inc. (Shire HGT) are discussing with the European Medicines Agency (EMEA)